Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, GNT Biotech - LARVOL DELTA

EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. (PubMed, Cell Death Dis) - "We inferred that STAT1 was the key driver of the synergistic effect using RNA-seq and ChIP-seq analysis. Our findings provide sufficient preclinical evidence in support of a potential combination therapy strategy for TCL patients."

Journal • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • STAT1

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: The Affiliated Hospital of Xuzhou Medical University

New P2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study. (PubMed, Oncologist) - P2 | "The combination of HDACi and tislelizumab with chemotherapy showed promising antitumor effects and manageable toxicity. More studies are needed to further confirm these results."

Journal • P2 data • Hematological Disorders • Leukopenia • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

CHIDAMIDE, A HISTONE DEACETYLASES INHIBITOR, ALLEVIATES PANCREATIC FIBROSIS THROUGH THE HDAC1/E2F1/PIWIL1 POLYAMINE METABOLIC SIGNALING CASCADE (UEGW 2025) - No abstract available

Epigenetic controller • Fibrosis • Immunology • E2F1 • HDAC1

ADVANCES IN DLBCL MANAGEMENT: HIGHLIGHTS FROM CHINA (ICML 2025) - "The DEB study is the first phase III trial to show that combining tucidinostat with R-CHOP regimen is a feasible and efficacious novel approach in previously untreated DLBCL patients with DE...Another study also shows promising prospects: polatuzumab vedotin, zanubrutinib, rituximab, and lenalidomide (Pola-ZR2) regimen in unfit or frail patients with DLBCL, the CR rate was 77% (17/22), and ORR was 86% (19/22). The Pola-ZR2 regimen demonstrates promising efficacy in unfit or frail patients with DLBCL. More clinical research results will be presented at this meeting."

IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Oncology • BCL2 • MYC

NOVEL ZCR (ZANUBRUTINIB, CHIDAMIDE, RITUXIMAB) ± CHOP REGIMEN DEMONSTRATES PROMISING EFFICACY IN FRONTLINE TREATMENT OF DOUBLE-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA (ICML 2025) - P2 | "This phase 2 trial demonstrates ZCR ± CHOP achieves superior CRR (83.3%) versus historical R-CHOP data, with manageable toxicity, and ctDNA emerges as a potential response-related biomarker. The findings provide evidence for chemotherapy reduction in DE-DLBCL through targeted induction strategies."

Clinical • Tumor mutational burden • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TMB

Molecularly targeted therapy strategies for adult T-cell leukemia/lymphoma (PubMed, Rinsho Ketsueki) - "Lenalidomide, an oral anticancer drug classified as an immunomodulator, showed an overall response rate of 46% in a phase II clinical trial in relapsed ATL. The antibody therapy mogamulizumab showed an overall response rate of 50% in a phase II trial of relapsed C-C motif chemokine receptor 4-positive ATL. Brentuximab vedotin has yet to show clear evidence of efficacy due to the limited number of patients enrolled in phase II trials...The EZH1/2 inhibitor valemetostat showed a response rate of 48% in a phase II trial in relapsed/refractory aggressive ATL. The histone acetylation inhibitor tucidinostat also exhibited efficacy in ATL, with an objective response rate of 30.4%. This review focuses on the abovementioned molecular-targeted agents, which are all currently used in Japan."

Journal • Review • Adult T-Cell Leukemia-Lymphoma • Gene Therapies • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Oral Cancer • CCR4 • EZH2

Chidamide, a novel histone deacetylase inhibitor, alleviates renal fibrosis by suppressing the PI3K/AKT signaling pathway. (PubMed, Biochem Pharmacol) - "RNA-seq and biochemical analyses further suggest that chidamide elicits an antifibrotic effect through the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. Collectively, these results suggest that chidamide may inhibit RF progression through the PI3K/AKT signaling pathway."

Journal • Breast Cancer • Fibrosis • Hematological Malignancies • Immunology • Lymphoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma • TGFB1

Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma: A Nonrandomized Clinical Trial. (PubMed, JAMA Dermatol) - P1/2 | "This all-oral combination may represent a new therapeutic option for advanced CTCL, particularly in mycosis fungoides. ClinicalTrials.gov Identifier: NCT06037239."

Clinical • Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Pruritus • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • PIK3CD

Chidamide impedes the progression of non-small cell lung cancer by inhibiting the METTL3/EPHA7 pathway. (PubMed, J Chemother) - "In vivo, chidamide treatment reduced EPHA7 protein expression by regulating METTL3, leading to inhibited tumor growth. Collectively, these findings identified the METTL3/EPHA7 axis as a key mediator of chidamide's anti-tumor effects, suggesting chidamide's potential as a novel therapeutic strategy for NSCLC."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EPHA7 • METTL3

MOLECULAR SUBTYPE-GUIDED R-MINE+X REGIMEN IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY (ICML 2025) - P=N/A | "To address this, we explored R-MINE by replacing conventional mitoxantrone with mitoxantrone hydrochloride liposome (Lipo-MIT) and incorporated molecular subtype-guided targeted agents (X) into the R-MINE+X regimen for R/R DLBCL...The R-MINE+X regimen (rituximab 375 mg/m2, d0; Lipo-MIT 12‒20 mg/m2, d1; ifosfamide 1.33 g/m2, d1‒3; etoposide 65 mg/m2, d1‒3) was administered for up to 3 cycles (each cycle lasting 21 days). Targeted combinations: MCD/BN2 (BTK inhibitors), EZB (chidamide), TP53 mutation (PD-1 monoclonal antibody), other subtypes (lenalidomide/investigator's choice)... The R-MINE+X regimen exhibited favorable tolerability and clinically meaningful efficacy in R/R DLBCL."

Clinical • IO biomarker • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

OPTIMAL TREATMENT FOR DOUBLE-EXPRESSOR LYMPHOMA IN THE ERA OF NOVEL AGENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS (ICML 2025) - " PubMed, OVID, Cochrane Library, and clinical trial registries were systematically searched (up to February 2025) for for studies on the treatment with R-CHOP, R-DA-EPOCH, or R-CHOP+X [including BTK inhibitors (BTKi), polatuzumab vedotin, lenalidomide, venetoclax, tucidinostat, and bortezomib] in newly diagnosed DEL. The current study suggested that R-CHOP plus novel agents offered significant benefit over R-CHOP alone in DEL, with BTKi and tucidinostat as top options for improvement of PFS and CR rate, respectively."

IO biomarker • Retrospective data • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • MYC

Therapeutic approaches to primary NRAS-driven leptomeningeal melanoma (EACR 2025) - "Additionally, we report here that the top four drug hits from the FDA screen epirubicin, tucidinostat, dasatinib and valemetostat suppress proliferation in patient cells significantly more than in controls, with epirubicin having the greatest effect. Precision targeting of oncogenic NRAS driver alleles using siRNA is more promising than repurposing of small molecule inhibitors in currently untreatable leptomeningeal dysplasia and melanoma, potentially in combination with trametinib."

Melanoma • Oncology • Solid Tumor • ARL6IP1 • BIRC5 • CASP3 • CASP7 • NRAS

Efficacy of tucidinostat pre-emptive therapy for peripheral T-cell lymphoma after allogeneic stem cell transplantation. (PubMed, Intern Med) - "The patient has maintained complete remission for 2-years. Thus, given its mechanism, tucidinostat may be a viable option for post-transplant therapy."

Journal • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation

Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China. (PubMed, Front Oncol) - "In this study, 82.9% of patients received a CHOP-like regimen, while 36.4% also received chidamide...Our novel prognostic model, along with the Chinese AITL score, may enhance the identification of Chinese patients at varying risks for chemotherapy. Furthermore, the pathological marker CD7 is anticipated to emerge as a significant biomarker for the prognostic evaluation of AITL."

Clinical data • Journal • Real-world evidence • Retrospective data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD7

A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) (ICML 2025) - P1, P3 | "All pts had received chemotherapy; moreover, all had been treated with tucidinostat or brentuximab vedotin (tucidinostat, 59 [88.1%]; brentuximab vedotin, 21 [31.3%]; both, 13 [19.4%]). The pivotal study met its primary endpoint, demonstrating that SHR2554 is efficacious and has a manageable safety profile in pts with r/r PTCL. Our findings position SHR2554 as a new potential therapeutic option for this challenging-to-treat population. A randomized controlled phase 3 study comparing SHR2554 with standard therapy for r/r PTCL is currently underway (NCT06122389)."

Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • EZH2

CHIDAMIDE IN COMBINATION WITH AZACITIDINE, MITOXANTRONE LIPOSOMES, AND PREDNISONE (CAMP REGIMEN) FOR TREATMENT-NAÏVE TFH-DERIVED PERIPHERAL T-CELL LYMPHOMA (ICML 2025) - "Chidamide combined with azacitidine, mitoxantrone liposome and prednisone (CAMP regimen) in the treatment of treatment-naïve TFH-derived PTCL has a high complete response rate and a controllable safety profile, which is expected to become a new treatment option for treatment-naïve TFH-derived PTCL, but the cohort needs to be further expanded to verify its safety and efficacy."

Combination therapy • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A PHASE II STUDY OF AZACITIDINE AND CHIDAMIDE PLUS CHOP VERSUS CHOP IN PREVIOUSLY UNTREATED PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (ICML 2025) - "Despite the modest increase in CR rate, the addition of chidamide and azacitidine to the CHOP regimen did not demonstrate a significant improvement in PFS or ORR compared to the CHOP regimen for patients with untreated PTCL."

Clinical • P2 data • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A NOVEL TREATMENT REGIMEN FOR NEWLY DIAGNOSED CAEBV INDUCING A HIGH RESPONSE RATE: PD-1 INHIBITOR, L-ASPARGASE AND CHIDAMIDE (ICML 2025) - "The study aims to explore an effective and safe regimen for CAEBV: PD-1 inhibitor Sintilimab, L-asparaginase-class drug Pegaspargase, and histone deacetylase inhibitor Chidamide (P-P-Chi). The P-P-Chi regimen demonstrated significant efficacy and favorable safety in CAEBV as a first-line therapy, warranting further clinical trials and broader application."

Lymphoma

REAL-WORLD STUDY OF GOLIDOCITINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA: RETROSPECTIVE DATA FROM MEDICAL CENTERS IN CHINA (ICML 2025) - P1/2 | "golidocitinib combination therapies were administered in 32 (55.2%) patients, including 12 (20.7%) patients combined with chemotherapy, 10 (17.2%) patients combined with chidamide, 7 (12.1%) patients combined with immune-checkpoint inhibitors and 3 (5.2%) patients combined with other agents as per physician's choice. Death due to adverse reactions occurred in 2 (3.3%) patients: 1 (1.7%) due to pulmonary infection and 1 (1.7%) due to gastrointestinal hemorrhage. The first Real-world data showed a favorable efficacy and acceptable safety profiles of golidocitinib based therapies in heavily pretreated patients with R/R PTCL, which align with clinical trial outcomes."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

REAL WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES FOR CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA (ICML 2025) - "Brentuximab vedotin (BV), a CD30-targeted agent, has demonstrated notable efficacy and safety profiles across a range of diverse CD30-positive (CD30+) lymphomas and has been widely applied worldwide...Among 23 (8.6%) R/R pts, a diverse range of treatment regimens was noticed, with 9 pts and 7 pts receiving chidamide-containing and GemOx-like respectively... To our knowledge, this is the first study to describe the treatment patterns and outcomes in broader Chinese population, which is instrumental in optimizing treatment strategies. The CHOP-like regimen was the predominant modality for ND pts in our study and a variety of regimens were adopted among R/R pts. Moreover, there is no established standard of care globally for R/R pts and diverse options were employed in clinical practice, which was associated with poor prognosis."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

TISLELIZUMAB COMBINED WITH CPEL (CHIDAMIDE, PREDNISONE, ETOPOSIDE, LENALIDOMIDE) FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (ICML 2025) - "This study investigates a novel salvage strategy combining anti-PD-1 antibody tislelizumab with chidamide, prednisone, etoposide and lenalidomide (CPEL) as introduction therapy, followed by risk-adapted consolidation with autologous hematopoietic stem cell transplantation (ASCT) and tislelizumab and bendamustine (TB) in R/R HL. Anti-PD-1 antibody-based T-CPEL induction regimen demonstrates promising efficacy with manageable toxicity in R/R cHL. Consolidation through ASCT and TB optimize long-term outcomes. These findings warrant validation in larger prospective cohorts."

Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

NOVEL ROLE OF CHIDAMIDE IN TAM REPROGRAMMING AND IMMUNOTHERAPY ENHANCEMENT THROUGH RNA SPLICING (ICML 2025) - "Chidamide enhances anti-lymphoma efficacy by promoting M1 polarization, independent of its HDAC targets. It targets the splicing factor SF1, promoting M1 polarization through specific splicing products, SETD4-L and PPWD1-L. This unique mechanism underlies chidamide's superior clinical outcomes and its ability to improve immunotherapy efficacy by modulating the tumor microenvironment."

IO biomarker • Lymphoma • Natural Killer/T-cell Lymphoma • GLI2 • HDAC1 • PPWD1

LOW-DOSE INVOLVED-SITE RADIOTHERAPY (LD-ISRT) COMBINED WITH HDAC INHIBITORS AS A BRIDGE TO CAR T-CELL THERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) AND NON-HODGKIN LYMPHOMA (NHL) WITH EXTRAMEDULLARY OR EXTRANODAL INVOLVEMENT: A SINGLE-CENTER, INVESTIGATOR-INITIATED STUDY (EHA 2025) - "After bridging, patients received standard fludarabine 25mg/m2 and cyclophosphamide 250mg/m2 lymphodepletion followed by CAR T-cell infusion on different targets, such as BCMA, GPRC5D in R/R MM and CD19, CD20, CD22, or CD79b in R/R B-cell NHL.With a median follow-up of 6.2 months, the best overall response rate (ORR) was 83%. The combination of LD-ISRT and chidamide as a bridging strategy before CAR-T cell therapy yielded promising efficacy in relapsed/refractory hematologic malignancies, particularly in patients with extramedullary disease. Building on prior research, this approach leverages epigenetic reprogramming-mediated modulation of the tumor microenvironment to enhance CAR-T cell infiltration, offering a potential solution to CAR-T resistance. These findings warrant further investigation in larger cohorts."

CAR T-Cell Therapy • Clinical • IO biomarker • Anemia • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • CD20 • CD22 • CD79B • TP53

REAL-WORLD STUDY OF GOLIDOCITINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: RETROSPECTIVE DATA FROM MEDICAL CENTERS IN CHINA (EHA 2025) - P1/2 | "golidocitinib combination therapies were administered in 32 (55.2%) patients, including 12 (20.7%) patients combined with chemotherapy, 10 (17.2%) patients combined with chidamide, 7 (12.1%) patients combined with immune-checkpoint inhibitors and 3 (5.2%) patients combined with other agents as per physician's choice. The first real-world data showed a favorable efficacy and acceptable safety profiles of golidocitinib based therapies in R/R PTCL, which align with clinical trial results. Further studies are warranted to explore the potential combination therapies."

Real-world • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia